How is SPI Pharma Preparing to Face the Future of Healthcare?


SPI Pharma, one of Our Road to CPhI Milano sponsors discuss how they are preparing to face the future of healthcare.

The Mission of the Company

SPI Pharma’s mission is making a difference — in the lives of patients, their customers, their employees. and the communities that they serve. SPI strives to make a difference for patients by offering delivery platforms that provide dosages that are easy to take, easy to administer, and provide better regimen adherence; for their employees by providing a challenging and aspirational workplace; to communities by being a thoughtful member; and to their customers through innovative formulations and platforms that reduce development time and increase speed to market.

In the pharmaceutical market, SPI Pharma makes a difference by continually seeking out new solutions to their customers’ challenges, driven by unmet patient needs, regulatory challenges, and regional preferences. The company closely follows trends in disease, dosing, and the formulation challenges associated with small and large molecule APIs. In particular, SPI Pharma has assembled a team that values continuous learning and organizational agility focused on advancing their customers’ aspirations. Rather than merely providing what customers need, SPI is constantly thinking about their customers’ customers and what they need, broadening their understanding of the market, and anticipating new and forthcoming needs, opportunities, products, and applications, before customers ask or even realize those needs themselves. Beyond the primary focus on serving their customers, SPI Pharma maintains a focus on the patient and the caregiver, particularly for patients with special needs or adherence challenges, such as pediatric and geriatric populations.

As such, the company’s expansion strategy rests with the answer to the following question: What platform can we create to improve a patient’s health and make life easier for the caregiver? What kind of delivery systems can we develop to provide multiple treatment options that best suit the patient?

SPI Pharma’s short-term focus is on providing quality, reliable products, underpinned by strong product and regulatory support. Over the mid-to-long term, the company is focused on formulation and platform development, product line extensions, and continuing to build strong partnerships. SPI has joint development partnerships with many different companies ranging from big pharma, who appreciate the ways in which SPI enhances the speed to market for their programs, to small and midsize innovators, who particularly value SPI’s formulation and regulatory expertise. For example, SPI Pharma has partnered with Purisys LLC in a joint effort focused on enhancing absorption, release profile, bioavailability, and higher cannabidiol (CBD) efficacy in convenient finished dosages.

SPI Pharma is currently ramping up new product development and is proud to announce the expansion of their line of Mannogem® Mannitols with the launch of the Precious Gem Collection by SPI Pharma, featuring four new mannitol products.

Additionally, SPI is expanding their Sorbitol Special® manufacturing capability with a new, state-of-the-art facility at their Grand Haven, Michigan, site.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

SPI Pharma

SPI Pharma provides formulation innovation and support to pharmaceutical clients in more than 55 countries. Its products include antacid actives, excipients, taste-masking and fast-dissolve technologies, drug delivery systems for tablets, and a variety of other innovations for patient-friendly dosage forms. The company’s functional excipients can be used in a wide range of customer applications, including soft chew, chewable, swallow tablets, lozenges, orally disintegrating, and soft gel dosage forms. SPI Pharma is headquartered in Wilmington, Delaware, and has locations across the United States, France, and India.

SPI Pharma is a leading supplier of solutions to pharmaceutical formulation marketers worldwide. The company’s primary objective is to engineer functional materials that enable their customers to solve formulation problems, achieve differentiation, and gain speed to market. Through collaboration with our customers, SPI uses proven processing skills and formulation expertise to deliver value-added and cost-effective solutions to their customers’ problems.